Abbott's Nutrition pivot: defensive volume strategy masks deeper portfolio concentration

What happened

Abbott's Nutrition segment, which saw Q1 sales decline 6%, is shifting to a volume-driven strategy involving pricing adjustments and new product launches. This move acknowledges weakness in a historically stable segment, but the company's overall growth continues to rely on Medical Devices, which posted 8.1% ex-FX growth. Meanwhile, the Exact Sciences integration is absorbing management attention and driving SG&A costs up $679M YoY. The Nutrition pivot appears defensive rather than opportunistic, as the segment faces structural headwinds from changing consumer preferences and competition. Investors should view this not as a catalyst but as a confirmation that Abbott's core growth engines are narrowing to Medical Devices alone.

Implication

The volume-led Nutrition strategy may stabilize the segment but likely at the expense of margins, adding near-term earnings pressure on top of Exact Sciences dilution. Investors should wait for evidence that volume growth doesn't erode profitability before reconsidering the stock.

Thesis delta

Previously, the thesis assumed Nutrition would remain a stable, modest-growth contributor. The shift to a volume-driven strategy after a 6% sales decline signals that Nutrition is now a turnaround story, not a steady cash generator. This increases execution risk and narrows the growth narrative to Medical Devices alone, reducing the margin of safety and requiring higher conviction on CGM and cardio momentum to justify the current valuation.